Mesoblast (ASX:MSB) was the top performer for the year up 835% (as of December 30). On December 18 Mesoblast announced that the US Food and Drug Administration (FDA) had finally approved its therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback